{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:24:57Z","timestamp":1787063097974,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant Number: 72074123"],"award-info":[{"award-number":["Grant Number: 72074123"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant Number: 72304150"],"award-info":[{"award-number":["Grant Number: 72304150"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11096-024-01824-9","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T04:07:59Z","timestamp":1732507679000},"page":"196-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost-effectiveness of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a comparative analysis in China, the United\u00a0States and Europe"],"prefix":"10.1007","volume":"47","author":[{"given":"Yuyang","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongting","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baolong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-8061","authenticated-orcid":false,"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"issue":"10127","key":"1824_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/s0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301\u201314. https:\/\/doi.org\/10.1016\/s0140-6736(18)30010-2.","journal-title":"Lancet"},{"issue":"3","key":"1824_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1824_CR3","unstructured":"Globocan Cancer Observatory. Data version: 2022 [online]. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/160-china-fact-sheet.pdf. Accessed 19 Apr 2024."},{"issue":"1","key":"1824_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-021-00245-6","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):7. https:\/\/doi.org\/10.1038\/s41572-021-00245-6.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"1824_CR5","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3760\/cma.j.cn501113-20230717-00006","volume":"31","author":"National Clinical Research Center for Infectious Diseases; Society of Hepatology, Beijing Medical Association; Translational Medicine Branch, China Association of Gerontology and Geriatrics","year":"2023","unstructured":"National Clinical Research Center for Infectious Diseases; Society of Hepatology, Beijing Medical Association; Translational Medicine Branch, China Association of Gerontology and Geriatrics. Expert consensus on precise diagnosis and management of primary hepatocellular carcinoma in advanced stage. Zhonghua Gan Zang Bing Za Zhi. 2023;31(9):910\u201320. https:\/\/doi.org\/10.3760\/cma.j.cn501113-20230717-00006.","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"10","key":"1824_CR6","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1111\/j.1478-3231.2010.02292.x","volume":"30","author":"PJ Chen","year":"2010","unstructured":"Chen PJ, Furuse J, Han KH, et al. Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts\u2019 opinion. Liver Int. 2010;30(10):1427\u201338. https:\/\/doi.org\/10.1111\/j.1478-3231.2010.02292.x.","journal-title":"Liver Int"},{"issue":"4","key":"1824_CR7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390. https:\/\/doi.org\/10.1056\/NEJMoa0708857.","journal-title":"N Engl J Med"},{"issue":"2","key":"1824_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11096-023-01675-w","volume":"46","author":"P Zhang","year":"2024","unstructured":"Zhang P, Zhang L, Xu K, et al. Evaluating the impact of PD-1 inhibitor treatment on key health outcomes for cancer patients in China. Int J Clin Pharm. 2024;46(2):429\u201338. https:\/\/doi.org\/10.1007\/s11096-023-01675-w.","journal-title":"Int J Clin Pharm"},{"issue":"20","key":"1824_CR9","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med"},{"issue":"7","key":"1824_CR10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/s1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22(7):977\u201390. https:\/\/doi.org\/10.1016\/s1470-2045(21)00252-7.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1824_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77\u201390. https:\/\/doi.org\/10.1016\/s1470-2045(21)00604-5.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1824_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1159\/000529636","volume":"12","author":"P Merle","year":"2023","unstructured":"Merle P, Kudo M, Edeline J, et al. Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: longer term follow-up from the phase 3 KEYNOTE-240 trial. Liver Cancer. 2023;12(4):309\u201320. https:\/\/doi.org\/10.1159\/000529636.","journal-title":"Liver Cancer"},{"issue":"4","key":"1824_CR13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/s1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571\u201380. https:\/\/doi.org\/10.1016\/s1470-2045(20)30011-5.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1824_CR14","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","volume":"9","author":"S Qin","year":"2023","unstructured":"Qin S, Kudo M, Meyer T, et al. Tislelizumab versus Sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol. 2023;9(12):1651\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4003.","journal-title":"JAMA Oncol"},{"key":"1824_CR15","unstructured":"Chinese National Medical Products Administration. Notice of Drug Approval Documentation Delivered on January 2, 2024. [online]. https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20240102151646109.html. Accessed 13 May 2024."},{"key":"1824_CR16","unstructured":"Tevimbra | European Medicines Agency (EMA) [online]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tevimbra#product-details. Accessed 12 Oct 2024."},{"key":"1824_CR17","unstructured":"Drug Approval Package: CTEVIMBRA. U.S. Food and Drug Administration (FDA) [online]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/761232Orig1s000TOC.cfm. Accessed 12 Oct 2024."},{"key":"1824_CR18","doi-asserted-by":"publisher","first-page":"1356244","DOI":"10.3389\/fpubh.2024.1356244","volume":"12","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Lin Y, Cai H. Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis. Front Public Health. 2024;12:1356244. https:\/\/doi.org\/10.3389\/fpubh.2024.1356244.","journal-title":"Front Public Health"},{"issue":"2","key":"1824_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"1824_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067975","volume":"376","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022;376: e067975. https:\/\/doi.org\/10.1136\/bmj-2021-067975.","journal-title":"BMJ"},{"issue":"2","key":"1824_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0037","volume":"4","author":"D Su","year":"2021","unstructured":"Su D, Wu B, Shi L. Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open. 2021;4(2): e210037. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0037.","journal-title":"JAMA Netw Open"},{"key":"1824_CR22","unstructured":"Chinese Pharmaceutical Association. Chinese Pharmacoeconomic Evaluation Guidelines (2020). https:\/\/www.cpa.org.cn\/cpadmn\/attached\/file\/20201203\/1606977380634185.pdf. Accessed 01 Mar 2024."},{"key":"1824_CR23","unstructured":"Oxford University Press. Methods for the Economic Evaluation of Health Care Programmes. https:\/\/nibmehub.com\/opac-service\/pdf\/read\/Methods%20for%20the%20Economic%20Evaluation%20of%20Health%20Care%20Programmes.pdf. Accessed 01 Mar 2024."},{"key":"1824_CR24","unstructured":"Statistical bulletin of National Economic and social development of the People\u2019s republic of China in 2022. National Bureau of statistics of China (2022). [online]. https:\/\/data.stats.gov.cn\/easyquery.htm?cn=C01&zb=A0201&sj=2022l. Accessed 5 Apr 2024."},{"issue":"22","key":"1824_CR25","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1002\/cncr.34457","volume":"128","author":"Y Li","year":"2022","unstructured":"Li Y, Liang X, Li H, et al. Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Cancer. 2022;128(22):3995\u20134003. https:\/\/doi.org\/10.1002\/cncr.34457.","journal-title":"Cancer"},{"key":"1824_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.743979","volume":"12","author":"J Chen","year":"2021","unstructured":"Chen J, Tong X, Han M, et al. Cost-effectiveness of short-course radiation plus Temozolomide for the treatment of newly diagnosed glioblastoma among elderly patients in China and the United States. Front Pharmacol. 2021;12: 743979. https:\/\/doi.org\/10.3389\/fphar.2021.743979.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1824_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.33393\/grhta.2024.3018","volume":"11","author":"A Messori","year":"2024","unstructured":"Messori A, Romeo MR, Fadda V et al. Costs and benefits in patients with NYHA class III heart failure treated with CardioMEMS in Italy. Glob Reg Health Technol Assess. 2024;11(1):105\u20137. https:\/\/doi.org\/10.33393\/grhta.2024.3018.","journal-title":"Glob Reg Health Technol Assess"},{"issue":"10","key":"1824_CR28","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.jval.2024.06.003","volume":"27","author":"R Heine","year":"2024","unstructured":"Heine R, Mathijssen RHJ, Verbeek FAJ, et al. Market Entry Agreements for innovative pharmaceuticals subject to indication broadening: a case study for Pembrolizumab in The Netherlands. Value Health. 2024;27(10):1367\u201372. https:\/\/doi.org\/10.1016\/j.jval.2024.06.003.","journal-title":"Value Health"},{"issue":"9","key":"1824_CR29","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.vaccine.2023.01.058","volume":"41","author":"AM Getaneh","year":"2023","unstructured":"Getaneh AM, Li X, Mao Z, et al. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: evaluation for six European countries. Vaccine. 2023;41(9):1623\u201331. https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.058.","journal-title":"Vaccine"},{"key":"1824_CR30","unstructured":"Exchange-Rates.org. World currency exchange rates and historical rates. [online]. https:\/\/www.exchange-rates.org\/exchange-rate-history\/. Accessed 5 Apr 2024."},{"issue":"7","key":"1824_CR31","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jval.2020.03.010","volume":"23","author":"A Wiksten","year":"2020","unstructured":"Wiksten A, Hawkins N, Piepho HP, et al. Nonproportional hazards in network meta-analysis: efficient strategies for model building and analysis. Value Health. 2020;23(7):918\u201327. https:\/\/doi.org\/10.1016\/j.jval.2020.03.010.","journal-title":"Value Health"},{"issue":"15","key":"1824_CR32","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/sim.1203","volume":"21","author":"P Royston","year":"2002","unstructured":"Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21(15):2175\u201397. https:\/\/doi.org\/10.1002\/sim.1203.","journal-title":"Stat Med"},{"key":"1824_CR33","doi-asserted-by":"publisher","first-page":"8505","DOI":"10.1200\/JCO.2022.40.16_suppl.8505","volume":"40","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Han L, Wu L, et al. Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: an international randomized phase 3 study. J Clin Oncol. 2022;40:8505. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.8505.","journal-title":"J Clin Oncol"},{"key":"1824_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/e22040447","author":"R Rossi","year":"2020","unstructured":"Rossi R, Murari A, Gaudio P, et al. Upgrading model selection criteria with goodness of fit tests for practical applications. Entropy (Basel). 2020. https:\/\/doi.org\/10.3390\/e22040447.","journal-title":"Entropy (Basel)."},{"key":"1824_CR35","unstructured":"National Health Commission of the People\u2019s Republic of China [online]. http:\/\/www.nhc.gov.cn\/. Accessed 18 Mar 2024."},{"key":"1824_CR36","unstructured":"National Comprehensive Cancer Network. Guidelines-Treatment by Cancer Type. [online]. https:\/\/www.nccn.org\/guidelines\/category_1. Accessed 15 Apr 2024."},{"key":"1824_CR37","unstructured":"Data.CMs.gov. Centers for Medicare & Medicaid Services [online]. https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug\/. Accessed 5 May 2024."},{"key":"1824_CR38","unstructured":"IBM. RED BOOK Online\u00ae\/ Micromedex. [online]. http:\/\/www.micromedexsolutions.com. Accessed 17 Apr 2024."},{"key":"1824_CR39","unstructured":"U.S. Department of Veterans Affairs. The Pharmaceutical pricing data of the Federal Supply Schedule (FSS) Service [online]. https:\/\/www.va.gov\/opal\/nac\/fss\/pharmprices.asp. Accessed 17 Apr 2024."},{"key":"1824_CR40","unstructured":"The Centers for Medicare & Medicaid Services. Medicare Fee Schedule (2022) [online]. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search. Accessed 6 May 2024."},{"key":"1824_CR41","unstructured":"Medicines Complete [online]. https:\/\/www.medicinescomplete.com\/#\/search\/bnf\/tis?offset=0. Accessed 15 Apr 2024."},{"key":"1824_CR42","unstructured":"NHS Electronic Drug Tariff. Basic Prices of Drugs Product List [online]. https:\/\/www.drugtariff.nhsbsa.nhs.uk\/#\/00852760-DD\/DD00852586\/Part%20VIIIA%20products%20L. Accessed 27 Apr 2024."},{"key":"1824_CR43","unstructured":"Base de donn\u00e9es publique des m\u00e9dicaments [online]. https:\/\/base-donnees-publique.medicaments.gouv.fr\/index.php#result. Accessed 11 Apr 2024."},{"key":"1824_CR44","unstructured":"Tandv\u00e5rds\u2014och l\u00e4kemedelsf\u00f6rm\u00e5nsverket [online]. https:\/\/www.tlv.se\/beslut\/sok-priser-och-beslut-i-databasen.html?product=Indapamide&tab=1. Accessed 18 Mar 2024."},{"key":"1824_CR45","unstructured":"National Cost Collection for the NHS. The 2021\/22 National Cost Collection data [online]. https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/. Accessed 15 Apr 2024."},{"key":"1824_CR46","unstructured":"FRED Economic Data. Economic Research: Federal Reserve Bank of St Louis. Consumer Price Index for all urban consumers [online]. https:\/\/fred.stlouisfed.org\/series\/CPIMEDSL. Accessed 15 May 2024."},{"key":"1824_CR47","unstructured":"Chinese Society of Clinical Oncology. Beijing Xisike Clinical Oncology Research Foundation [online]. http:\/\/www.csco.ac.cn\/. Accessed 4 Mar 2024."},{"issue":"15","key":"1824_CR48","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/jco.23.02745","volume":"42","author":"JD Gordan","year":"2024","unstructured":"Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J Clin Oncol. 2024;42(15):1830\u201350. https:\/\/doi.org\/10.1200\/jco.23.02745.","journal-title":"J Clin Oncol"},{"key":"1824_CR49","unstructured":"European Society for Medical Oncology. Annals of Oncology (2023) [online]. https:\/\/www.esmo.org\/. Accessed 4 Mar 2024."},{"key":"1824_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.869960","volume":"10","author":"M Zhao","year":"2022","unstructured":"Zhao M, Pan X, Yin Y, et al. Cost-effectiveness analysis of five systemic treatments for unresectable hepatocellular carcinoma in china: an economic evaluation based on network meta-analysis. Front Public Health. 2022;10: 869960. https:\/\/doi.org\/10.3389\/fpubh.2022.869960.","journal-title":"Front Public Health"},{"issue":"5","key":"1824_CR51","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s11096-024-01752-8","volume":"46","author":"J Wei","year":"2024","unstructured":"Wei J, Xu K, Lin Y, et al. Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China. Int J Clin Pharm. 2024;46(5):1189\u201399. https:\/\/doi.org\/10.1007\/s11096-024-01752-8.","journal-title":"Int J Clin Pharm"},{"key":"1824_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110543","volume":"122","author":"Y Shu","year":"2023","unstructured":"Shu Y, Tang Y, Ding Y, et al. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma. Int Immunopharmacol. 2023;122: 110543. https:\/\/doi.org\/10.1016\/j.intimp.2023.110543.","journal-title":"Int Immunopharmacol"},{"key":"1824_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.906956","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Liang X, Li H, et al. Nivolumab versus Sorafenib as first-line therapy for advanced hepatocellular carcinoma: a cost-effectiveness analysis. Front Pharmacol. 2022;13: 906956. https:\/\/doi.org\/10.3389\/fphar.2022.906956.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1824_CR54","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/liv.14795","volume":"41","author":"F Wen","year":"2021","unstructured":"Wen F, Zheng H, Zhang P, et al. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis in China and the United states. Liver Int. 2021;41(5):1097\u2013104. https:\/\/doi.org\/10.1111\/liv.14795.","journal-title":"Liver Int"},{"key":"1824_CR55","unstructured":"Yaozhiwang. Health Industry Big Data Service and Empowerment Platform [online]. https:\/\/www.yaozh.com\/. Accessed 18 Mar 2024."},{"key":"1824_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.906956","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Liang X, Li H et al. Nivolumab versus Sorafenib as first-line therapy for advanced hepatocellular carcinoma: a cost-effectiveness analysis. Front Pharmacol. 2022;13: 906956.","journal-title":"Front Pharmacol"},{"issue":"10","key":"1824_CR57","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.14309\/ajg.0000000000000715","volume":"115","author":"ND Parikh","year":"2020","unstructured":"Parikh ND, Singal AG, Hutton DW et al. Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms. Am J Gastroenterol. 2020;115(10):1642\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1824_CR58","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.33761","volume":"4","author":"CL Chiang","year":"2021","unstructured":"Chiang CL, Chan SK, Lee SF et al. Cost-effectiveness of pembrolizumab as a second-line therapy for hepatocellular carcinoma. JAMA Netw Open. 2021;4(1): e2033761.","journal-title":"JAMA Netw Open"},{"key":"1824_CR59","doi-asserted-by":"publisher","first-page":"1103055","DOI":"10.3389\/fimmu.2022.1103055","volume":"13","author":"K Liu","year":"2022","unstructured":"Liu K, Zhu Y, Zhu H. Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis. Front Immunol. 2022;13:1103055.","journal-title":"Front Immunol"},{"key":"1824_CR60","doi-asserted-by":"publisher","first-page":"1205700","DOI":"10.3389\/fonc.2023.1205700","volume":"13","author":"NSH Xander","year":"2023","unstructured":"Xander NSH, Fiets WE, Uyl-de Groot CA. Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands. Front Oncol. 2023;13:1205700.","journal-title":"Front Oncol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-024-01824-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T02:54:54Z","timestamp":1737082494000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-024-01824-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1824"],"URL":"https:\/\/doi.org\/10.1007\/s11096-024-01824-9","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"7 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}